Literature DB >> 12652115

Use of cardiovascular drugs after acute myocardial infarction: a marked shift towards evidence-based drug therapy.

Asmund Reikvam1, Elena Kvan, Ivar Aursnes.   

Abstract

OBJECTIVE: To investigate the prescription pattern for cardiovascular drugs among patients discharged after an acute myocardial infarction (AMI) in hospitals that had participated in a corresponding study seven years earlier, and examine what the indications were for use of the different drugs.
METHODS: From 16 hospitals we drew a sample of patients who were discharged with a diagnosis of AMI during a three months period in 1999/2000. Physicians in each hospital obtained from the medical records the observed rate of use of cardiovascular drugs at discharge. The drug use was compared with findings from a corresponding sample drawn in 1993. The main indication for use of the different cardiovascular drugs was recorded for the 1999/2000 sample.
RESULTS: 399 patients discharged alive were included in the first study and 767 in the second. The use of beta-blockers, ACE inhibitors and statins rose substantially during the period. For patients aged </=70 drug use in respectively 1993 and 1999/2000 was as follows: beta-blockers 73% vs 89%, ACE inhibitors 14% vs 29%, statins not recorded vs 82%; corresponding figures for patients aged >70 were: beta-blockers 45% vs 74%, ACE inhibitors 19% vs 38%, statins not recorded vs 35%. Aspirin/anticoagulant use was largely unchanged; 93% and 70% of patients aged </=70 and >70 respectively used these drugs at the second survey. The use of regular nitrates and calcium antagonists had decreased. Nearly half of the >70 group and one-fifth of persons </=70 used 5-9 cardiovascular drugs.
CONCLUSIONS: At the end of the 1990s a substantial shift in drug therapy after AMI occurred, with a markedly increased use of drugs proven to be effective in clinical trials and less use of other cardiovascular drugs. The most frequently reported main indication for use of drugs was secondary prevention. The principles of evidence-based drug therapy became increasingly adopted among clinicians during the 1990s.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12652115     DOI: 10.1023/a:1022194604260

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  4 in total

1.  Practising what is preached: the MINAP study.

Authors:  O C Raffel; H D White
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

2.  Thrombolytic treatment in diabetic patients with acute myocardial infarction: lower rates of use than in non-diabetic patients are explained by differences in presenting ECGs.

Authors:  E Kvan; A Reikvam
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

3.  The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction.

Authors:  Elena Kvan; Aasmund Reikvam
Journal:  Eur J Clin Pharmacol       Date:  2004-03-19       Impact factor: 2.953

4.  Health-related quality of life after myocardial infarction is associated with level of left ventricular ejection fraction.

Authors:  Kjell I Pettersen; Elena Kvan; Arnfinn Rollag; Knut Stavem; Aasmund Reikvam
Journal:  BMC Cardiovasc Disord       Date:  2008-10-12       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.